Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00455689 · ClinicalTrials.gov registry record · Phase 4

Understanding Experimentally Induced Hot Flushes

A Phase 4 study, sponsored by Massachusetts General Hospital.

Completed
Registry status
Phase 4
Development phase
20
Enrollment target

NCT00455689: Completed Phase 4 study, sponsored by Massachusetts General Hospital.

NCT00455689 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00455689, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
Phase 4
Development phase
20 participants
Enrollment target

Study Summary

The purpose of the study is to examine the impact of hot flushes on sleep, mood, and well-being. The investigators will cause hot flushes by giving study participants the hormone medication, leuprolide (Lupron), which is a manufactured (artificial) hormone that makes the body think that it has reached menopause temporarily. Most women begin to have hot flushes within 4 weeks after taking leuprolide and resume menses 3 months later. The investigators will administer questionnaires to evaluate changes in sleep and mood over the course of the study.

Interventions

  • DRUG Leuprolide acetate

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2005-11-28
Est. Completion 2007-09-02
Phase Phase 4

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT00455689

The ClinicalTrials.gov registry entry for NCT00455689 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Leuprolide acetate is the first listed.

NCT00455689 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00455689 about?

NCT00455689 is a clinical study titled "Understanding Experimentally Induced Hot Flushes". The purpose of the study is to examine the impact of hot flushes on sleep, mood, and well-being. The investigators will cause hot flushes by giving study participants the hormone medication, leuprolide (Lupron), which is a manufactured (artificial) hormone that makes the body think that it has reach...

What is the current status of trial NCT00455689?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2005-11-28. Estimated completion is 2007-09-02.

What interventions are being tested in trial NCT00455689?

The interventions under investigation include: Leuprolide acetate (DRUG).

Who is sponsoring clinical trial NCT00455689?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.